LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Generated: 2026-11-17
Case ID: NM_001003841.3_c.517G_A_20261117_020650
Framework: ACMG/AMP 2015
Variant classification summary

NM_001003841.3:c.517G>A

SLC6A19  · NP_001003841.1:p.(Asp173Asn)  · NM_001003841.3
GRCh37: chr5:1212453 G>A  ·  GRCh38: chr5:1212338 G>A
Gene: SLC6A19 Transcript: NM_001003841.3
Final call
VUS
PS3 supporting BP4 moderate
All criteria require review: For research and educational purposes only.
Gene
SLC6A19
Transcript
NM_001003841.3
Protein
NP_001003841.1:p.(Asp173Asn)
gnomAD AF
0.003103546148516582 (v4.1)
ClinVar
Pathogenic
OncoKB
Interpretation summary
Generated evidence synthesis
1
PS3 supporting: D173N showed reduced or altered B0AT1 transport and surface expression in orthogonal oocyte assays.
2
BP4 moderate: REVEL 0.179 meets the generic missense threshold for BP4 moderate.
Final determination: Under the generic ACMG/AMP 2015 fallback, the applied PS3 supporting and BP4 moderate criteria satisfy neither a pathogenic nor a benign combination, so the call is VUS.
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
Criterion Status Rationale Evidence used
PVS1 N/A Not applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a missense variant.
pvs1_generic_framework generic_acmg_combination_rules
PS1 Not assessed Not assessed: D173N is reported, but no pathogenic alternate-nucleotide change producing the same Asp173Asn substitution is documented.
clinvar PMID:17555458
PS2 Not assessed Not assessed: no documented affected proband with confirmed maternity and paternity, parental genotypes, and absent family history is available.
PS3 Met Met at supporting: D173N showed relatively low amino-acid transport in oocytes compared with wild type, with orthogonal assays demonstrating altered transport and surface expression.
PMID:19185582
PS4 Not assessed Not assessed: D173N is reported in Hartnup families, but no verifiable matched control count, OR/RR, or 95% CI is available for the >5.0 PS4 requirement.
PMID:17555458 gnomad_v2 gnomad_v4
PM1 Not assessed Not assessed: no approved domain or hotspot evidence places residue 173 in a critical region without benign variation.
hotspots
PM2 Not met Not met: gnomAD v4.1 AF is 0.00310355, above the <=0.0001 PM2 threshold, with 12 homozygotes observed.
gnomad_v4 gnomad_v2
PM3 Not assessed Not assessed: no affected-proband observation with a pathogenic variant confirmed in trans by parental or offspring phase testing is documented.
PMID:17555458 PMID:18484095
PM4 N/A Not applicable: PM4 requires a protein-length change, and this is a missense variant.
pvs1_generic_framework generic_acmg_combination_rules
PM5 Not assessed Not assessed: no confirmed pathogenic alternate missense substitution at residue 173 is documented; the known D173N reports are the target change itself.
pm5_candidates PMID:17555458
PM6 Not assessed Not assessed: no affected-patient de novo observation is documented, even without parental maternity and paternity confirmation.
PP1 Not assessed Not assessed: papers mention D173N in unrelated families and recessive cosegregation, but provide no variant-specific affected-member genotypes or informative-meiosis count.
PMID:17555458 PMID:18484095
PP2 Not assessed Not assessed: the evidence lacks both a gene-level low-benign-missense measure and a systematic demonstration that missense is the common disease mechanism.
PMID:17555458 PMID:19185582
PP3 Not met Not met: REVEL 0.179 is below the generic PP3 supporting threshold of >=0.644 for missense variants.
revel
PP4 Not assessed Not assessed: Hartnup disorder is named, but no individual phenotype or family-history details establish the highly specific PP4 requirement.
clinvar PMID:15286788
PP5 Not met Not met: ClinVar has 0 expert-panel submissions for the exact variant, so laboratory and aggregate pathogenic labels cannot trigger PP5.
clinvar
BA1 Not met Not met: gnomAD v4.1 grpmax FAF is 0.00395819, below the 0.05 BA1 threshold, with 1,179,944 observed European non-Finnish alleles.
gnomad_v4 gnomad_v2
BS1 Not met Not met: gnomAD v4.1 grpmax FAF is 0.00395819, below the generic 0.01 BS1 default, and the allele is a documented common recessive Hartnup disease allele.
gnomad_v4 gnomad_v2 PMID:17555458
BS2 Not assessed Not assessed: gnomAD v4.1 reports 12 homozygotes, but their adult health status, ages, phenotypes, and expected early full penetrance are not documented.
gnomad_v4
BS3 Not met Not met: D173N showed relatively low transporter activity and altered surface expression rather than demonstrating no damaging effect on protein function or splicing.
PMID:19185582
BS4 Not assessed Not assessed: no affected, variant-negative relatives or family-level non-segregation analysis is documented.
BP1 Not met Not met: recurrent disease-associated missense D173N and direct functional testing show that SLC6A19 disease is not established as primarily truncating.
PMID:17555458 PMID:19185582
BP2 Not assessed Not assessed: no documented cis or trans observation with a pathogenic variant and confirmed phase meets the BP2 definition.
BP3 N/A Not applicable: BP3 requires an in-frame indel in a repeat region, and this is a missense variant.
pvs1_generic_framework generic_acmg_combination_rules
BP4 Met Met at moderate strength: REVEL 0.179 meets the generic BP4 moderate threshold of <=0.183 for missense variants.
revel
BP5 Not assessed Not assessed: no affected case with this variant and a confirmed alternate molecular diagnosis is documented.
BP6 Not met Not met: no exact-variant expert-panel benign or likely benign classification is present; available ClinVar submissions are non-expert assertions.
clinvar
BP7 N/A Not applicable: BP7 requires a synonymous variant, and this is a missense variant.
generic_acmg_combination_rules
Disclaimer: The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.